The Hollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD with the assistance of a senior leadership team, and together they represent the strong functional nexus of this matrix-based Center. The team is comprised of eight associate directors, each of whom has outstanding expertise in their area of responsibility. They are: Anthony J. Alberg, PhD, MPH, Associate Director of Cancer Control; Marvella E. Ford, PhD, Associate Director of Cancer Disparities; Anita L. Harrison, MPA, Associate Director of Administration; Philip H. Howe, PhD, Associate Director of Basic Sciences; Michael B. Lilly, MD, Associate Director of Translational Research; Steven A. Rosenzweig, PhD, Associate Director of Shared Resources; Melanie B. Thomas, MD, Associate Director of Clinical Investigations; Dennis K. Watson, PhD, Associate Director of Education & Training; and Kevin F. Staveley-O'Carroll, MD, PhD, Medical Director of the HCC Clinical Service Line. The HCC senior leadership team meets once a month as a formal Executive Council, one-on-one with the Director at least monthly, and more frequently with each other and the Director in the context of various HCC board/committee meetings. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director. Dr. Kraft has charged the senior leadership with employing consensus-building techniques as they work directly with the program leaders, shared resource directors, and various HCC boards and committees in formulating center-wide priorities, strategies, and allocation of resources. They work together as a team to ensure consistency in the mission, vision, and goals of the Center and develop synergistic interactions among the basic, translational, and clinical elements of the Center. They provide feedback on the growth of the HCC in their area of responsibility, which is particularly important given the rapid growth of the HCC, and evolving research directions at the national level. Based on this, they plan and implement proactive, integrative approaches for development of the research base, resources, and a formal strategic plan. The consistency of vision is particularly important in effectively leveraging all available resources at MUSC and at the state and national levels and engagement of the community in outreach activities.

Public Health Relevance

Support is requested for the senior leadership of the Hollings Cancer Center. This leadership is critical to ensuring the overall success of the Center in meeting its mission and goals and in the strategic planning and evaluation of all Center efforts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Medical University of South Carolina
United States
Zip Code
Bai, Aiping; Bielawska, Alicja; Rahmaniyan, Mehrdad et al. (2018) Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem 26:6067-6075
Graboyes, Evan M; Kompelli, Anvesh R; Neskey, David M et al. (2018) Association of Treatment Delays With Survival for Patients With Head and Neck Cancer: A Systematic Review. JAMA Otolaryngol Head Neck Surg :
Burris, Jessica L; Rivera-Rivera, Jessica N; Armeson, Kent et al. (2018) Causal attributions and their impact on psychosocial functioning in head and neck cancer patient-caregiver dyads: a preliminary, longitudinal study. Qual Life Res :
Bea, Vivian J; Cunningham, Joan E; Alberg, Anthony J et al. (2018) Alcohol and Tobacco Use in an Ethnically Diverse Sample of Breast Cancer Patients, Including Sea Island African Americans: Implications for Survivorship. Front Oncol 8:392
Panneer Selvam, Shanmugam; Roth, Braden M; Nganga, Rose et al. (2018) Balance between senescence and apoptosis is regulated by telomere damage-induced association between p16 and caspase-3. J Biol Chem 293:9784-9800
Wrangle, John M; Velcheti, Vamsidhar; Patel, Manish R et al. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol 19:694-704
Janakiraman, Harinarayanan; House, Reniqua P; Gangaraju, Vamsi K et al. (2018) The Long (lncRNA) and Short (miRNA) of It: TGF?-Mediated Control of RNA-Binding Proteins and Noncoding RNAs. Mol Cancer Res 16:567-579
Jin, Junfei; Lu, Zhongyang; Li, Yanchun et al. (2018) LPS and palmitate synergistically stimulate sphingosine kinase 1 and increase sphingosine 1 phosphate in RAW264.7 macrophages. J Leukoc Biol 104:843-853
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118

Showing the most recent 10 out of 536 publications